Share This Author
Romiplostim or standard of care in patients with immune thrombocytopenia.
Patients treated with romiplostim had a higher rate of a platelet response, lower incidence of treatment failure and splenectomy, less bleeding and fewer blood transfusions, and a higher quality of life than patients treated with the standard of care.
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
- L. Dirix, I. Takács, E. Hamilton
- Medicine, BiologyBreast Cancer Research and Treatment
- 23 October 2017
PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC, and showed an acceptable safety profile and clinical activity in a subset of patients with MBC.
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon…
- J. Hainsworth, M. Rubin, F. Greco
- Medicine, BiologyJournal of clinical oncology : official journal…
- 10 January 2013
In this large prospective trial, molecular tumor profiling predicted a tissue of origin in most patients with CUP and compares favorably with previous results using empiric CUP regimens.
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
Monoclonal gammopathy of undetermined significance: a consensus statement
The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.
Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Serum BCMA levels were found to be higher in the supernatants of cultured bone marrow mononuclear cells from multiple myeloma patients than in healthy subjects, and levels correlated with the change in tumour volume in response to melphalan or cyclophosphamide with bortezomib.
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
Brentuximab vedotin monotherapy may provide a frontline treatment option for older patients who cannot tolerate conventional combination chemotherapy for Hodgkin lymphoma, and preliminary data showed no substantial age-related changes in brentuxo-vedotin pharmacokinetics.
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly…
- H. Raftopoulos, W. Cooper, E. O’Boyle, N. Gabrail, R. Boccia, R. Gralla
- MedicineSupportive Care in Cancer
- 2 September 2014
A single subcutaneous APF530 injection offers a convenient alternative to palonosetron for preventing acute and delayed CINV after MEC or HEC.
Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized,…
- R. Boccia, L. Gordan, G. Clark, J. Howell, S. Grunberg
- MedicineSupportive Care in Cancer
- 12 September 2010
The GTDS provides effective, well-tolerated control of CINV associated with moderately or highly emetogenic multi-day chemotherapy and offers a convenient alternative route for delivering granisetron for up to 7 days that is as effective as oral granisettron.